874638-80-9

• 常用中文名：(2R)-2-脱氧-2-氟-2-甲基-D-赤式戊糖酸 γ-内酯 3,5-二苯甲酸酯
• 常用英文名：(2R)-2-Deoxy-2-fluoro-2-methyl-D-erythropentonic acid gamma-lactone 3,5-dibenzoate
• CAS号：874638-80-9
• 分子式：C₂₀H₁₇FO₆
• 分子量：372.344
• 相关类别： 医药中间体 原料药中间体
• 发布时间：2018-12-07 10:07:12
• 更新时间：2026-06-30 12:27:43

名称

• 中文名: (2R)-2-脱氧-2-氟-2-甲基-D-赤式戊糖酸 gamma-内酯 3,5-二苯甲酸酯
• 英文名: (2R)-2-Deoxy-2-fluoro-2-methyl-D-erythropentonic acid gamma-lactone 3,5-dibenzoate
• 中文别名: (2R)-2-脱氧-2-氟-2-甲基-D-赤式戊糖酸γ-内酯3,5-二苯甲酸酯; 索非布韦中间体2(-8); (2R)-2-脱氧-2-氟-2-甲基-D-赤式戊糖酸 GAMMA-内酯 3,5-二苯甲酸; 索菲布韦中间体1; (2R)-2-脱氧-2-氟-2-甲基-D-赤式戊糖酸 GAMMA-内酯 3,5-二苯甲酸酯(索菲布韦中间体1); (2R)-2-脱氧-2-氟-2-甲基-D-赤式戊糖; 索弗布韦中间体SFA-9; 3,5-二苯甲酰基-2-去氧-2-氟-2甲基-D-核糖-γ-内酯; 3,5-二苯甲酰基-2-去氧-2-氟-2-甲基-D-核糖-Γ-内酯(索非布韦中间体); 索菲布韦中间体 874-9; 索磷布韦杂质6; [(2R,3R,4R)-3-(苯甲酰氧基)-4-氟-4-甲基-5-氧代四氢呋喃-2-基]苯甲酸甲酯; (2R,3R,4R)-3-苯甲酰氧基-4-氟-4-甲基-5-氧代-2-苯甲酰氧甲基四氢呋喃; 索福斯布韦杂质N; 索磷布韦杂质; (2R)-2-脱氧-2-氟-2-甲基-D-赤式戊糖酸 GAMMA-内酯 3,5-二苯甲酸酯; (2R)-2-脱氧-2-氟-2-甲基-D-赤式戊糖酸 Γ-内酯 3,5-二苯甲酸酯; 索非布韦杂质46; 3,5-二苯甲酰基-2-去氧-2-氟-2甲基-D-核糖-Γ-内酯; ((2R,3R,4R)-3-(苯甲酰基氧基)-4-氟-4-甲基-5-氧代四氢呋喃-2-基)甲基 苯甲酸; ((2R,3R,4R)-3-(苯甲酰氧基)-4-氟-4-甲基-5-氧代四氢呋喃-2-基)甲基苯甲酸酯; 3,5-二苯甲酰基-2-去氧-2-氟-2-甲基; (2R)-2-脱氧-2-氟-2-甲基-D-赤式戊糖酸Γ-内酯3,5-二苯甲酸酯(索氟布韦中间体); ((2R,3R,4R)-3-(苄氧基)-4-氟-4-甲基-5-氧代四氢呋喃-2-基)甲基苯甲酸酯// 索菲布韦中间体; 索氟布韦内酯; ((2R,3R,4R)-3-(苯甲酰氧基)-4-氟-4-甲基-5-羰基四氢呋喃-2-基)甲基苯甲酸酯; 索弗布韦中间体; (2R,3R,4R) -2-氟-2-甲基- 3-苯甲酰氧基-4-(苯甲酰氧基)甲基-4-丁内酯; 索非布韦中间体4; 索氟布韦 中间体 SF-X1; 索非布韦中间体1; ((2R,3R,4R)-3 - (苯酰氧基)-4 - 氟-4 - 甲基-5 – 氧代四氢呋喃 -2 - 基)甲基 苯甲酸酯; 索非布韦中间体2; (2R)-2-脱氧-2-氟-2-甲基-D-赤式戊糖酸GAMMA-内酯3,5-二苯甲酸酯索菲布韦中间体; 索氟布韦杂质9; 索弗布韦中间体2; 索福布韦杂质N; 索非布韦中间体-3,5-二苯甲酰基-2-去氧-2-氟-2甲基-D-核糖-Γ-内酯; 索非布韦杂质; (2R)-2-脱氧-2-氟-2-甲基-D-赤式戊糖酸; 3,5-二苯甲酰基-2-去氧-2-氟-2-甲基-D-核糖-Γ-内酯(索非布韦中间体-5); 索菲布韦中间体; ((2R,3R,4R)-3-(苄氧基)-4-氟-4-甲基-5-氧代四氢呋喃-2-基)甲基苯甲酸酯; K91,(2R)-2-脱氧-2-氟-2-甲基-D-赤式戊糖酸 Γ-内酯 3,5-二苯甲酸酯; 索非布韦IMP-2; 索非布韦杂质30; 索氟布韦 中间体3; 索氟布伟中间体SF-X1
• 英文别名: (2R-3R,4R)-3-(Benzoyzxy)-4-Fluoro-4-Methyl-5-Oxotetrahydrofuran-2Yl)Methyl Benzoate; (2R,3R,4R)-3- (benzoyoxy)-4-fluoro-4-methyl-5-oxotetrahydrofuran-2yl)methyl Benzoate; SofosBuvir Impurity 46; 3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-D-ribono-γ-latone; ((2R,3S,4R)-3-(benzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydrofuran-2-yl)methyl benzoate; (2R)-2-Deoxy-2-fluoro-2-methyl-D-erythropentonic acid γ-lactone 3,5-dibenzoate; (2R) -2-Deoxy-2-Fluoro-2-Methyl-D-Erythropentonic Acid y-Lactone 3,5-Dibenzoate; 3,5-Di-O-benzoyl-2-deoxy-2-fluoro-2C-methyl-D-ribono-1,4-lactone; 3. ((2R,3R,4R)-3-(benzoyloxy)-4-fluoro-4-Methyl-5-oxotetra; ((2R,3R,4R)-3-(BENZOYLOXY)-4-FLUORO-4-METHYL-5-OXOTETRAHYDROFURAN-2-YL)METHYL BENZOATE 874-9; 4-amino-1-[(2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidin-2-one; ((2R,3R,4R)-3-(benzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydrofuran-2-yl)methyl benzoate ISO 9001：2015 REACH; (2R)-2-Deoxy-2-fluoro-2-methy-D- erythropentonic acid gamma-lactone 3,5- dibenzoate; Sofosbuvir INT 3; Sofosbuvir Impurity 30; (2R,3R,4R)-3-Benzoyloxy-4-fluoro-4-methyl-5-oxo-2-(benzoyloxymethyl)tetrahydrofuran; ((2R,3R,4R)-3-(benzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydrofuran-2-yl)methyl benzoate; Di-O-benzoyl-2-deoxy-2-fluoro-2-C-Methyl-D; PSI-6130 interMediate; D-erythro-Pentonic acid, 2-deoxy-2-fluoro-2-Methyl-, γ-lactone, 3,5-dibenzoate, (2R); (2R)-2-DEOXY-2-FLUORO-2-METHYL-D-ERYTHRO; (2R,3R,4R)-2-[(benzoyloxy)methyl]-4-fluoro-4-methyl-5-oxooxolan-3-yl benzoate; SF-X1; Sofosbuvir imp-2; (2R)-2-Deoxy-2-fluoro-2-Methyl-D-erythropentonic acid; ((2R,3R,4R)-3-(DENZOYLOXY)-4-FLUORO-4-METHYL-5-OXOTETRAHYDROFURAN-2-YL)METHYL BENZOATE; Sofosbuvir Intermediate 1; nterMediate of Sofosbuvir; Methyl ((2R,3R,4R)-3-(benzoyloxy)-4-fluoro-4-Methyl-5-oxotetrahydrofuran-2-yl) benzoate; 3,5-di-O-benzoyl-2-deoxy-2-fluoro-D-ribono-γ-latone; Sofosbuvir intermediate; 3,5-Di-O-benzoyl-2-deoxy-2-fluoro-2C-methyl-D-abino-1,4-lactone; 3,5-Di-O-benzoyl-2-deoxy-2-fluoro-2-C-Methyl-D-ribono-γ-lactone; (2R)-3,5-di-O-benzoyl-2-fluoro-2-C-methyl-D-ribono-r-lactone; (2R)-2-Deoxy-2-fluoro-2-Methyl-D-erythro-pentonic acid-g-lactone 3,5-dibenzoate; [(2R,3R,4R)-3-benzoyloxy-4-fluoro-4-methyl-5-oxooxolan-2-yl]methyl benzoate; (S)-isopropyl 2-(((S)-(((2R,3R,4R,5S)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate; [(2R,3R,4R)-3-(Benzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydro-2-furanyl]methyl benzoate; ((2R,3R,4R)-3-(benzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydro; ((2R,3R,4R)-3-(benzoyloxy)-4-fluoro-5-oxotetrahydrofuran-2-yl)methyl benzoate; InterMediate of Sofosbuvir; Sofosbuvir Impurity

物化性质

• 密度: 1.3±0.1 g/cm3
• 沸点: 458.6±34.0 °C at 760 mmHg
• 熔点: 133℃
• 分子式: C₂₀H₁₇FO₆
• 分子量: 372.344
• 闪点: 222.9±20.6 °C
• 精确质量: 372.100922
• PSA: 78.90000
• LogP: 4.07
• 蒸汽压: 0.0±1.1 mmHg at 25°C
• 折射率: 1.577
• 储存条件: 室温，干燥，密封

安全

• 危害码 (欧洲): Xi

合成路线

879551-04-9 98-88-4 ~89% 874638-80-9

文献：WO2006/31725 A2, ; Page/Page column 13; 30-31 ;

93635-76-8 ~% 874638-80-9

文献：US2013/72699 A1, ;

1351925-17-1 ~% 874638-80-9

文献：US2013/72699 A1, ;

1033394-83-0 ~% 874638-80-9

文献：US2013/72699 A1, ;

上下游产品

上游产品  5
879551-04-9 98-88-4 93635-76-8 1351925-17-1
1033394-83-0
下游产品  1
817204-32-3